Efficacy and safety of BCMA-directed CAR T-cell therapy in extramedullary relapsed or refractory multiple myeloma: a meta-analysis.

Front Immunol · 2026 · PMC13150449 · PMID 42112336

Europe PMC DOI

hedged sentence

0.2889

closest p · 5.8× alpha

0.2889

boldest claim

The sentences

did not reach statistical significanceP= 0.2889not close (p > 0.1)

The corresponding complete response rates were 42% (95%CI: 32%–51%) and 49% (95%CI: 40%–58%), a difference that did not reach statistical significance (I2= 90.7%, P= 0.2889).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.